norfloxacin [Ligand Id: 12408] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL9 (Baccidal, Chibroxin, MK-366, Norfloxacin, Norfloxacine, Norfloxacino, Noroxin, NSC-757250, Quinabic, Utinor) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| bromodomain containing 4/Bromodomain-containing protein 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1163125] [GtoPdb: 1945] [UniProtKB: O60885] | ||||||||
| ChEMBL | Inhibition of BRD4 (unknown origin) | B | 6.01 | pIC50 | 980 | nM | IC50 | Eur J Med Chem (2021) 213: 113137-113137 [PMID:33460833] |
| DNA gyrase subunit A/DNA gyrase subunit B/DNA gyrase in Escherichia coli (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2094139] [GtoPdb: 3217, 3218] [UniProtKB: P0AES4, P0AES6] | ||||||||
| ChEMBL | Inhibition of Escherichia coli DNA gyrase holoenzyme assessed as reduction in pBR322 DNA supercoiling using pBR322 plasmid DNA as substrate incubated for 90 mins in presence of ATP by ethidium bromide staining based agarose gel electrophoresis analysis | B | 4.73 | pIC50 | 18600 | nM | IC50 | Eur J Med Chem (2019) 167: 105-123 [PMID:30769240] |
| ChEMBL | Inhibition of Escherichia coli DNA gyrase | B | 4.73 | pIC50 | 18600 | nM | IC50 | Eur J Med Chem (2020) 199: 112326-112326 [PMID:32460040] |
| ChEMBL | Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922 | B | 6.22 | pIC50 | 600 | nM | IC50 | J Med Chem (2006) 49: 39-42 [PMID:16392790] |
| GABAA receptor π subunit/GABAA receptor β1 subunit/GABAA receptor δ subunit/GABAA receptor γ2 subunit/GABAA receptor α5 subunit/GABAA receptor α3 subunit/GABAA receptor γ1 subunit/GABAA receptor α2 subunit/GABAA receptor α4 subunit/GABAA receptor γ3 subunit/GABAA receptor α6 subunit/GABAA receptor α1 subunit/GABAA receptor β3 subunit/GABAA receptor β2 subunit/GABAA receptor ε subunit/GABA-A receptor; anion channel in Rat (target type: PROTEIN COMPLEX GROUP) [ChEMBL: CHEMBL1907607] [GtoPdb: 419, 410, 416, 414, 408, 406, 413, 405, 407, 415, 409, 404, 412, 411, 417] [UniProtKB: O09028, P15431, P18506, P18508, P19969, P20236, P23574, P23576, P28471, P28473, P30191, P62813, P63079, P63138, Q91ZM7, Q9ES14] | ||||||||
| ChEMBL | Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M | B | 4.89 | pIC50 | 13000 | nM | IC50 | J Med Chem (1993) 36: 1356-1363 [PMID:8388467] |
| ChEMBL | Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M | B | 7.7 | pIC50 | 20 | nM | IC50 | J Med Chem (1993) 36: 1356-1363 [PMID:8388467] |
| Multidrug resistance protein mdtK in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1681613] [UniProtKB: P37340] | ||||||||
| ChEMBL | Binding affinity to Escherichia coli K-12 multidrug efflux protein YdhE expressed in Escherichia coli AG100AX in presence of 0.02% DDM surfactant by fluorescence polarization assay | B | 4.01 | pKd | 98400 | nM | Kd | Antimicrob Agents Chemother (2008) 52: 3052-3060 [PMID:18591276] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Bres1 | F | 4.12 | pIC50 | 75000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antimicrobial activity against Plasmodium falciparum | F | 4.12 | pIC50 | 75000 | nM | IC50 | Bioorg Med Chem (2010) 18: 2225-2231 [PMID:20185316] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 | F | 4.13 | pIC50 | 74600 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against synchronized Plasmodium falciparum K1 | F | 4.17 | pIC50 | 67000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against asynchronous Plasmodium falciparum 3D7 | F | 4.18 | pIC50 | 66000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against synchronized Plasmodium falciparum CS2 | F | 4.23 | pIC50 | 59000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FCR3 | F | 4.23 | pIC50 | 58600 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 | F | 4.26 | pIC50 | 55300 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against asynchronous Plasmodium falciparum CS2 | F | 4.26 | pIC50 | 55000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against synchronized Plasmodium falciparum 3D7 | F | 4.26 | pIC50 | 55000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Palo Alto | F | 4.27 | pIC50 | 54100 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| ChEMBL | Antiplasmodial activity against asynchronous Plasmodium falciparum K1 | F | 4.27 | pIC50 | 54000 | nM | IC50 | Eur J Med Chem (2018) 146: 1-14 [PMID:29360043] |
| Topoisomerase IV subunit A in S.aureus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4088] [UniProtKB: P0C1U9] | ||||||||
| ChEMBL | Inhibition of topoisomerase 4 decatenation in Staphylococcus aureus ATCC 29213 | B | 5.46 | pIC50 | 3500 | nM | IC50 | J Med Chem (2006) 49: 39-42 [PMID:16392790] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
